Innovative drug WYY026B injection, a subsidiary of Dezhan Health (000813.SZ), was approved for clinical trial of a new drug by the US FDA

Zhitong Finance App News, Dezhan Health (000813.SZ) announced that Beijing Honghuixin Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Honghuixin”), a wholly-owned subsidiary of the company, recently received a notice from the US Food and Drug Administration (hereinafter referred to as “US FDA”). The WYY026B injection drug clinical trial application declared by Honghuixin has been approved by the US FDA to carry out relevant clinical research.

WYY026B injection is an innovative chemical class 1 drug developed by Honghuixin and has independent intellectual property rights. Pre-clinical pharmacodynamics studies have shown remarkable therapeutic effects, improving neurological function scores and reducing the area of cerebral infarctions; mechanistic studies have shown that WYY026B can improve brain tissue hypoxia by enhancing the degree of oxygen utilization in brain tissue, and also has antioxidant and anti-inflammatory effects. The clinical trial application for this drug was recently approved by the US FDA, which agreed to carry out clinical research on this drug in accordance with the submitted plan.

The application for clinical trials of WYY026B injection in the US has been approved. It is an important step forward in the drug development process and will further enhance the company's core competitiveness in cardiovascular drug research and development.